home / stock / pnexf / pnexf quote
Last: | $400 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $400 |
High: | $0 |
Low: | $0 |
Volume: | 16,660 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$400 | $0 | $400 | $0 | $0 | 16,660 | 07-13-2023 |
$0.04 | $0 | $0.04 | $0 | $0 | 19,800,000 | 05-08-2023 |
$0.04 | $0 | $0.04 | $0 | $0 | 19,800,000 | 05-05-2023 |
$0.04 | $0 | $0.04 | $0 | $0 | 31,700,000 | 04-04-2023 |
$0.04 | $0 | $0.04 | $0 | $0 | 29,700,000 | 03-20-2023 |
$0.04 | $0 | $0.04 | $0 | $0 | 18,166,000 | 03-08-2023 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 100 | 09-20-2022 |
$0.0005 | $0.0005 | $0.0005 | $0.0005 | $0.0005 | 200 | 09-09-2022 |
$0.001 | $0.001 | $0.001 | $0.001 | $0.001 | 1,000 | 08-17-2022 |
$0.001 | $0.001 | $0.001 | $0.001 | $0.001 | 2,000 | 08-16-2022 |
$0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 150 | 03-11-2022 |
$0.11 | $0.11 | $0.11 | $0.11 | $0.11 | 2,040 | 01-31-2022 |
$0.11 | $0.11 | $0.11 | $0.11 | $0.11 | 1,400 | 01-27-2022 |
$0.025 | $0.025 | $0.025 | $0.025 | $0.025 | 2,040 | 12-27-2021 |
$0.15 | $0.15 | $0.15 | $0.15 | $0.15 | 850 | 11-26-2021 |
$0.14 | $0.14 | $0.14 | $0.14 | $0.14 | 5,000 | 11-17-2021 |
$0.5 | $0.5 | $0.5 | $0.5 | $0.5 | 5,000 | 10-07-2021 |
$0.55 | $0.55 | $0.55 | $0.55 | $0.55 | 1,000 | 10-04-2021 |
$0.6 | $0.6 | $0.6 | $0.6 | $0.6 | 300 | 09-21-2021 |
$0.96 | $0.96 | $0.96 | $0.96 | $0.96 | 1,080 | 09-06-2021 |
News, Short Squeeze, Breakout and More Instantly...
Pharnext SA Company Name:
PNEXF Stock Symbol:
OTCMKTS Market:
PARIS, FRANCE / ACCESSWIRE / January 4, 2023 / Pharnext SA (FR001400BV89:ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson a...
PARIS, FRANCE / ACCESSWIRE / March 31, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the 'Company'), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PL...
€6 million capital raise priced at market with warrants subscribed by two existing shareholders, €5 million convertible bonds issued to European investors, European investors have also provided written indication of strong interest for the potential of additional ...